Side-by-side · Research reference

PTD-DBMvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/40 cited

BPhase 3HUMAN-REVIEWED9/42 cited

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

PTD-DBM

VIP

Primary target

CXXC5–Dishevelled protein-protein interaction

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Not applicable — pathway derepression rather than receptor agonism

Yes — exogenous VIP acts as physiological agonist

Origin

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

PTD-DBM

VIP

Wound healing protocol

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

—

Hair regeneration protocol

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

—

Evidence basis

Animal models only (mice)

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Co-administration

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

—

Human translation

No published human studies

—

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

04Side Effects & Safety

Parameter

PTD-DBM

VIP

Reported adverse events

None reported in animal studies

—

Wnt pathway activation risks

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

—

Long-term safety

Unknown — no chronic dosing or human data

—

Delivery vehicle effects

HA-PG hydrogel well-tolerated in mice; human translation pending

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

PTD-DBM

VIP

1. Wound Healing Protocol (Animal Model)

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Hair Regeneration Protocol (Animal Model)

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Combination Therapy

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage & Handling

Not disclosed in available literature. Peptide stability and storage conditions not published.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Storage

—

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.